To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

Inclusion criteria

• Patients able to understand and sign a document of informed consent;
• Patients aged ≥49 years with age-related cataract formation;
• Patients planning to undergo surgical removal of cataract by phacoemulsification with implantation of a posterior chamber intraocular lens;
• Patients that have healthy eyes excluding the formation of cataract.

Exclusion criteria

• pseudoexfoliation syndrome with glaucoma or zonular compromise in the operative eye;
• A congenital ocular anomaly (e.g., aniridia, congenital cataract) in the operative eye;
• Iris atrophy in the operative eye;
• Glaucoma (including pseudoexfoliation or pigmentary) or any causes of compromised outflow in the operative eye;
• Any abnormality which prevents reliable Goldmann applanation tonometry in the operative eye;
• Ocular hypertension (lntraocular Pressure (IOP) > 21 mmHg) in the operative eye at the baseline exam;
• Corneal abnormality that results in a poor endothelial cell photograph and prevents reliable endothelial cell density measurement;
• Baseline endothelial cell density < 1500 cells/mm2, in the operative eye;
• Planned multiple procedures during cataract/Intraocular Lens (IOL) implantation surgery (e.g., trabeculoplasty, corneal transplant). NOTE: A minor relaxing keratotomy
• Patients 48 years of age or younger;
• Proliferative diabetic retinopathy in the operative eye;
• Uncontrolled diabetes mellitus;
• Marfan's Syndrome;
• An ocular disease and/or condition that may compromise results;
• A history of chronic or recurrent inflammatory eye disease (e.g. iritis, scleritis, uveitis, iridocyclitis, rubeosis iritis) in the operative eye;
• Lens for the correction of astigmatism may be performed;
• Previous ocular trauma to the operative eye (this includes previous intraocular surgery and traumatic cataract). NOTE: history of non-invasive laser surgery (with the exception of laser treatment for PDR) is acceptable for inclusion;
• A non-functional fellow eye;
• Participation in any other clinical study within the 30 days before surgery